Positron emission tomography analysis of [11C]KW‐6002 binding to human and rat adenosine A2A receptors in the brain

Adenosine A2A receptors are found on striatal neurones projecting to the external pallidum. KW‐6002 (istradefylline) is a potent and selective antagonist for the adenosine A2A receptors in the CNS and acts to inhibit the excessive activity of this pathway in the MPTP marmoset model of PD, thus relieving parkinsonism. The objectives of this study were to investigate the regional binding of the novel positron emission tomography tracer [11C]KW‐6002 in the healthy human brain and the rat brain, along with receptor occupancy by cold KW‐6002 at varying doses in human. The highest [11C]KW‐6002 uptake in the rat brain was seen in striatum and lower levels in cortex and cerebellum. Brain [11C]KW‐6002 uptake was well characterized in humans by a two‐tissue compartmental model with a blood volume term, and the ED50 of cold KW‐6002 was 0.5 mg in the striatum. Over 90% receptor occupancy was achieved with daily oral doses of greater than 5 mg. In humans, blockable binding was present in all gray matter structures including the cerebellum, which has not been reported to express A2A receptors. MRS 1745, an A2B receptor selective antagonist, had no effect on the cerebellar binding of [11C]KW‐6002 in rats, suggesting that this blockable signal is unlikely to result from an affinity for adenosine A2B receptors. Synapse 62:671–681, 2008. © 2008 Wiley‐Liss, Inc.

[1]  T. Jones,et al.  Spectral Analysis of Dynamic PET Studies , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[2]  M. Williams,et al.  Direct autoradiographic localization of adenosine A2 receptors in the rat brain using the A2-selective agonist, [3H]CGS 21680. , 1989, European journal of pharmacology.

[3]  Hiroshi Kase,et al.  Adenosine A2A antagonists with potent anti-cataleptic activity , 1997 .

[4]  P M Bloomfield,et al.  The on-line monitoring of continuously withdrawn arterial blood during PET studies using a single BGO/photomultiplier assembly and non-stick tubing. , 1991, Medical progress through technology.

[5]  E. Ongini,et al.  Adenosine A2A Receptors and Neuroprotection , 1997, Annals of the New York Academy of Sciences.

[6]  Hiroshi Kase,et al.  Industry forum: Progress in pursuit of therapeutic A2A antagonists , 2003, Neurology.

[7]  T. Shindou,et al.  Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors , 2003, Neurology.

[8]  S. Ferré.  Adenosine-dopamine interactions in the ventral striatum Implications for the treatment of schizophrenia , 1997, Psychopharmacology.

[9]  T. Shindou,et al.  Adenosine A2A receptor enhances GABAA‐mediated IPSCs in the rat globus pallidus , 2001, The Journal of physiology.

[10]  C. Dourish,et al.  Potential for antipsychotic and psychotomimetic effects of A2A receptor modulation , 2003, Neurology.

[11]  J. Ribeiro,et al.  Adenosine A2 receptor-mediated excitatory actions on the nervous system , 1996, Progress in Neurobiology.

[12]  J. Gusella,et al.  Characterization and Expression of the Human A2a Adenosine Receptor Gene , 1996, Journal of neurochemistry.

[13]  B B Fredholm,et al.  Distribution of adenosine receptors in the postmortem human brain: An extended autoradiographic study , 1997, Synapse.

[14]  S. Gunn,et al.  Positron Emission Tomography Compartmental Models , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[15]  K. Ikeda,et al.  Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease , 2002, Journal of neurochemistry.

[16]  J. Moreau,et al.  Central adenosine A2A receptors: an overview , 1999, Brain Research Reviews.

[17]  L. Grégoire,et al.  Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys , 1999, Neurology.

[18]  J. Linden,et al.  Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system , 1998, The Journal of comparative neurology.

[19]  B. Fredholm,et al.  Pharmacology of adenosine A2A receptors. , 1996, Trends in pharmacological sciences.

[20]  J. Daval,et al.  Adenosine physiology and pharmacology: how about A2 receptors? , 1996, Pharmacology & therapeutics.

[21]  A. Gubitz,et al.  Tissue distribution of adenosine receptor mRNAs in the rat , 1996, British journal of pharmacology.

[22]  T. Shindou,et al.  The role of adenosine A2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons. , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[23]  P. Jenner,et al.  A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD , 2003, Neurology.

[24]  D L Hill,et al.  Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. , 1997, Medical physics.

[25]  K. Quirk,et al.  Solubilisation and immunoprecipitation of rat striatal adenosine A(2A) receptors. , 2001, European journal of pharmacology.

[26]  T. Shindou,et al.  Adenosine modulates the striatal GABAergic inputs to the globus pallidus via adenosine A2A receptors in rats , 2003, Neuroscience Letters.

[27]  D. Brooks,et al.  Evaluation of [4‐O‐methyl‐11C]KW‐6002 as a potential PET ligand for mapping central adenosine A2A receptors in rats , 2001, Synapse.

[28]  B. Fredholm,et al.  Further characterization of the binding of the adenosine receptor agonist [3H]CGS 21680 to rat brain using autoradiography , 1995, Neuropharmacology.

[29]  P. Jenner,et al.  Adenosine A2A Antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in Parkinsonian monkeys , 1998, Annals of neurology.

[30]  S. Augood,et al.  Adenosine A2a receptor mRNA is expressed by enkephalin cells but not by somatostatin cells in rat striatum: a co-expression study. , 1994, Brain research. Molecular brain research.

[31]  T. Shindou,et al.  Binding of [3H]KF17837S, a selective adenosine A2 receptor antagonist, to rat brain membranes. , 1994, Molecular pharmacology.

[32]  Hiroshi Kase,et al.  Rescue of Locomotor Impairment in Dopamine D2 Receptor-Deficient Mice by an Adenosine A2A Receptor Antagonist , 2000, The Journal of Neuroscience.

[33]  B. Fredholm.  Purinoceptors in the nervous system. , 1995, Pharmacology & toxicology.

[34]  S. Schiffmann,et al.  Distribution of adenosine A2 receptor mRNA in the human brain , 1991, Neuroscience Letters.

[35]  P. Jenner,et al.  Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease. , 1997, Trends in pharmacological sciences.

[36]  J. Palacios,et al.  Adenosine A2 receptors: Selective localization in the human basal ganglia and alterations with disease , 1991, Neuroscience.

[37]  M. Ochi,et al.  Systemic administration of adenosine A2A receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study , 2000, Neuroscience.

[38]  J. Costentin,et al.  Adenosine A2A receptors and depression , 2003, Neurology.

[39]  Tzvetelina Dimitrova,et al.  Adenosine A2A receptor antagonist treatment of Parkinson’s disease , 2003, Neurology.

[40]  J. Hubble,et al.  Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD , 2003, Neurology.

[41]  T. Spinks,et al.  Physical characteristics of the ECAT EXACT3D positron tomograph. , 2000, Physics in medicine and biology.

[42]  M. Chiang,et al.  Characterization of the rat A2A adenosine receptor gene: a 4.8‐kb promoter‐proximal DNA fragment confers selective expression in the central nervous system , 2003, The European journal of neuroscience.

[43]  O. Hornykiewicz,et al.  Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. , 2004, Brain : a journal of neurology.

[44]  H. Kase,et al.  Distribution of adenosine A2A receptor antagonist KW-6002 and its effect on gene expression in the rat brain , 2002, Brain Research.

[45]  E. M. Adler,et al.  Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. , 1992, Brain research. Molecular brain research.

[46]  P. Jenner,et al.  Adenosine A2A receptors modify motor function in MPTP‐treated common marmosets , 1998, Neuroreport.

[47]  B. Fredholm,et al.  Evidence for high-affinity binding sites for the adenosine A2A receptor agonist [3H] CGS 21680 in the rat hippocampus and cerebral cortex that are different from striatal A2A receptors , 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.

[48]  E. Ongini,et al.  The selective adenosine A2A receptor antagonist SCH 58261 discriminates between two different binding sites for [3H]-CGS 21680 in the rat brain , 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.

[49]  K. Jacobson,et al.  Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. , 2000, Journal of medicinal chemistry.